Over the next several weeks Distillations will be talking to people with special insight into the coronavirus crisis—biomedical researchers, physicians, public health experts, and historians.
In this episode we speak with John C. Martin, a biomedical researcher and former CEO of Gilead Sciences. Gilead is a pharmaceutical giant best known for its antiviral therapies for HIV/AIDS and hepatitis, but it’s also the company behind remdesivir, an antiviral drug that has recently made headlines as a possible treatment for COVID-19.
Martin talked to senior producer Mariel Carr about remdesivir, antiviral treatments for HIV and other illnesses, and working with Anthony “Tony” Fauci.Credits
"Fauci: New Drug Remdesivir Cuts Down Coronavirus Recovery Time," NBC Nightly News. April 29, 2020.
Are you the creator of this podcast?
and pick the featured episodes for your show.
Connect with listeners
Podcasters use the RadioPublic listener relationship platform to build lasting connections with fansYes, let's begin connecting
Find new listeners
Understand your audience
Engage your fanbase